Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,494 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intervention 2 - Placebo Clear all

Conditions: Sedation, Anxiety, Pain
Interventions: Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03), Placebo NanoTab™; Drug
Lead sponsor: Talphera, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Biochemical Failure
Interventions: brassica intervention; Dietary Supplement
Lead sponsor: Vanderbilt University; Other
Eligibility: 40 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Lateral Canthal Lines, Crow's Feet
Interventions: ANT-1207, Botulinum Toxin Type A; Biological
Lead sponsor: Anterios Inc.; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Birmingham, Alabama • Miami Beach, Florida • West Palm Beach, Florida + 3 more

Conditions: Tetralogy of Fallot, Double Outlet Right Ventricle
Interventions: N-thymidine, Urine Collection, Echocardiogram, Cardiac MRI (CMR), Propranolol Hydrochloride, Placebo, Physical Exam, Specimen Collection; Other · Procedure · Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 30 Days to 100 Days
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 4
States / cities: New York, New York • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Chronic Pain
Interventions: BioPlete™ Advanced Formula, Placebo; Dietary Supplement
Lead sponsor: Ethos Research & Development; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Tampa, Florida • West Palm Beach, Florida

Conditions: Leukemia, Lymphoma, Oral Complications
Interventions: filgrastim, palifermin, cyclophosphamide, etoposide, ifosfamide, peripheral blood stem cell transplantation, quality-of-life assessment, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity
Interventions: Active transcranial direct current stimulation (tDCS), Hypocaloric diet, Sham transcranial direct current stimulation (tDCS); Device · Other
Lead sponsor: University of Sao Paulo; Other
Eligibility: 20 Years to 40 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Gynecology
Interventions: Metformin, Placebo, Endometrial Biopsy, Lifestyle Intervention, Questionnaires; Drug · Other · Procedure + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 50 Years to 65 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Heart Failure
Interventions: Whey protein powder and L-carnitine, Maltodextrin placebo powder and Psyllium Husk capsules; Dietary Supplement
Lead sponsor: University of Arkansas; Other
Eligibility: 60 Years to 90 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Migraine, Aura, Patent Foramen Ovale
Interventions: BioSTAR Septal Repair Implant System, Sham Procedure; Device · Procedure
Lead sponsor: NMT Medical; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Stamford, Connecticut • Seattle, Washington

Conditions: Postmenopause
Interventions: Bazedoxifene 10 mg/CE 0.625 mg, Bazedoxifene 20 mg/CE 0.625 mg, Bazedoxifene 40 mg/CE 0.625 mg, Bazedoxifene 10 mg/CE 0.45 mg, Bazedoxifene 20 mg/CE 0.45 mg, Bazedoxifene 40 mg/CE 0.45 mg, Raloxifene 60 mg, Placebo; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 22
States / cities: Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more

Conditions: Tobacco Dependence
Interventions: Varenicline, Nicotine patch, Placebo Patch, Placebo Pill; Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 1,251 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Alcoholism
Interventions: Alcohol, Placebo; Other
Lead sponsor: Indiana University; Other
Eligibility: 21 Years to 27 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Post Operative Urinary Retention
Interventions: Tamsulosin, Placebo; Drug
Lead sponsor: Jewish Hospital, Cincinnati, Ohio; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Peripheral Arterial Disease
Interventions: Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA); Drug · Behavioral · Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 40 Years to 80 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: COVID-19
Interventions: ALG-097558, Dabigatran, Itraconazole, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Myocardial Infarction
Interventions: TG100-115; Drug
Lead sponsor: TargeGen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Reaction Time
Interventions: Treatment (CopaPrime+ (USANA Health Sciences), Placebo; Dietary Supplement · Other
Lead sponsor: USANA Health Sciences; Industry
Eligibility: 18 Years to 30 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Park City, Utah

Conditions: Precancerous Condition, Stage 0 Melanoma, Stage I Melanoma, Stage II Melanoma
Interventions: lovastatin, placebo, biopsy, laboratory biomarker analysis; Drug · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 3
States / cities: Orange, California • Tampa, Florida • Salt Lake City, Utah

Conditions: Type 2 Diabetes
Interventions: Vestal DM Active device, Lifestyle modification, Vestal DM Sham device; Device · Behavioral
Lead sponsor: Neurovalens Ltd.; Industry
Eligibility: 22 Years to 70 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 15
States / cities: Birmingham, Alabama • La Jolla, California • Sacramento, California + 12 more

Conditions: Left Ventricular Dysfunction
Interventions: Adult stem cells, Placebo; Biological
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 21 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 5
States / cities: Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more

Conditions: Hypochondroplasia
Interventions: infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day; Drug
Lead sponsor: QED Therapeutics, a BridgeBio company; Industry
Eligibility: 3 Years to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more

Conditions: Knee Osteoarthritis
Interventions: High-speed power training, Slow-speed strength training; Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 55 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Metastatic Castration-resistant Prostatic Neoplasms
Interventions: Pasritamig, Placebo, Best Supportive Care (BSC), JNJ-87189401; Biological · Other · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 55
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 43 more

Search by objective public record fields.

A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure

Effects of Brassica or Indole-3-carbinol on Prostatectomy Patients With PSA Recurrence

Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet

Beta-blocker Administration for Cardiomyocyte Division

Evaluate the Use of the Foundation Pain Index and the Nutritional Supplement BioPlete™ in Adults With Chronic Pain

Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer

Noninvasive Neuromodulation of the Prefrontal Cortex in Subjects With Obesity

An Endometrial Cancer Chemoprevention Study of Metformin

Nutritional Therapy for Autonomic Dysfunction in Elderly Heart Failure Patients

MIST II PFO-Migraine Trial With BioSTAR® Bioabsorbable Septal Repair Implant

Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene

UW Quitting Using Intensive Treatment Study (QUITS)

GABRA2 and the Pharmacokinetics of Risk for Alcoholism (GPRA)

Tamsulosin to Prevent Postoperative Urinary Retention in Laparoscopic Inguinal Hernia Repair

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

Safety of TG100-115 for Heart Attack Treated With Angioplasty

The Acute Effects of a Dietary Supplement on Cognitive Performance in Highly Trained Athletes.

Lovastatin in Treating Patients At High Risk of Melanoma

Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control As a Means of Improving Glycemic Control in Adults with Type 2 Diabetes Mellitus

Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)

An Interventional Study of Infigratinib in Children With Hypochondroplasia

High-speed Power Training in Older Adults With Knee Osteoarthritis (OA)

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)